首页 > 最新文献

EJHaem最新文献

英文 中文
Safety and efficacy of ketamine use in patients with vaso-occlusive crisis: A systematic review and meta-analysis 在血管闭塞性危象患者中使用氯胺酮的安全性和有效性:系统回顾和荟萃分析。
Pub Date : 2024-11-25 DOI: 10.1002/jha2.1050
Ernesto Calderon Martinez, Stephin Zachariah Saji, Thomas Campos Carmona, Vaidarshi Abbagoni, Mohammad Salman, Mishell Estefanía Llerena Vargas, Suchita Mylavarapu, Druvini Fernando, Lakshmi Sheethal Arvapalli, Nathalia Schettino Samad, Nithin Karnan, Camila Sanchez Cruz

Introduction

Sickle cell disease (SCD) is characterized by acute episodes called vaso-occlusive crises (VOC). VOC is marked by severe pain due to blocked blood vessels by sickled cells. Ketamine has been reported to be effective and safe in managing VOC in SCD patients.

Objectives/methods

This review aims to determine ketamine's safety and efficacy through analysis of clinical trials and observational studies.

Methods

Adhering to PRISMA guidelines, this systematic review and meta-analysis systematically searched seven databases on May 20, 2024 for randomized control trials (RCT), cohorts, and case–control studies.

Results

Five studies with 689 participants met the inclusion criteria. A meta-analysis of two studies (518 observations) for the Numerical Rating Scale (NRS) pain score showed no significant difference, with a standardized mean difference (MD) of 0.23 (95% CI: −0.13 to 0.59, p = 0.21, I2 = 0%). For morphine milligram equivalent (MME), a meta-analysis of two studies (344 observations) resulted in an MD of −0.03 (95% CI: −0.09 to 0.04, p = 0.45, I2 = 97%). However, the side effects analysis from four studies (608 observations) showed a significantly higher relative risk (RR) of 5.74 (95% CI: 2.80–11.79, p < 0.0001, I2 = 0%) for mild side effects, including nausea, vomiting, and dizziness.

Conclusion

Ketamine qualitative synthesis shows potential for improving pain management in SCD patients during VOC, but without statistically significant differences in pain reduction. It is associated with increased mild side effects, though no severe adverse events were reported. Further research is needed to increase the sample size and power of the analysis to clarify optimal dosing and administration protocols for ketamine in this context.

简介:镰状细胞病(SCD)的特点是急性发作称为血管闭塞危象(VOC)。挥发性有机化合物的特点是由于镰状细胞阻塞血管而引起剧烈疼痛。据报道,氯胺酮在控制SCD患者的VOC方面是有效和安全的。目的/方法:本综述旨在通过临床试验和观察性研究的分析来确定氯胺酮的安全性和有效性。方法:本系统评价和荟萃分析遵循PRISMA指南,于2024年5月20日系统检索了7个数据库,包括随机对照试验(RCT)、队列和病例对照研究。结果:5项研究689名受试者符合纳入标准。数值评定量表(NRS)疼痛评分的两项研究(518项观察)的荟萃分析显示无显著差异,标准化平均差异(MD)为0.23 (95% CI: -0.13至0.59,p = 0.21, i2 = 0%)。对于吗啡毫克当量(MME),两项研究(344项观察)的荟萃分析得出MD为-0.03 (95% CI: -0.09至0.04,p = 0.45, i2 = 97%)。然而,来自4项研究(608项观察)的副作用分析显示,轻微副作用(包括恶心、呕吐和头晕)的相对风险(RR)显著较高,为5.74 (95% CI: 2.80-11.79, p 2 = 0%)。结论:氯胺酮定性合成有可能改善VOC期间SCD患者的疼痛管理,但在减轻疼痛方面无统计学意义。它与轻度副作用增加有关,但没有严重不良事件的报道。需要进一步的研究来增加样本量和分析的能力,以澄清在这种情况下氯胺酮的最佳剂量和给药方案。
{"title":"Safety and efficacy of ketamine use in patients with vaso-occlusive crisis: A systematic review and meta-analysis","authors":"Ernesto Calderon Martinez,&nbsp;Stephin Zachariah Saji,&nbsp;Thomas Campos Carmona,&nbsp;Vaidarshi Abbagoni,&nbsp;Mohammad Salman,&nbsp;Mishell Estefanía Llerena Vargas,&nbsp;Suchita Mylavarapu,&nbsp;Druvini Fernando,&nbsp;Lakshmi Sheethal Arvapalli,&nbsp;Nathalia Schettino Samad,&nbsp;Nithin Karnan,&nbsp;Camila Sanchez Cruz","doi":"10.1002/jha2.1050","DOIUrl":"10.1002/jha2.1050","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Sickle cell disease (SCD) is characterized by acute episodes called vaso-occlusive crises (VOC). VOC is marked by severe pain due to blocked blood vessels by sickled cells. Ketamine has been reported to be effective and safe in managing VOC in SCD patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives/methods</h3>\u0000 \u0000 <p>This review aims to determine ketamine's safety and efficacy through analysis of clinical trials and observational studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Adhering to PRISMA guidelines, this systematic review and meta-analysis systematically searched seven databases on May 20, 2024 for randomized control trials (RCT), cohorts, and case–control studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Five studies with 689 participants met the inclusion criteria. A meta-analysis of two studies (518 observations) for the Numerical Rating Scale (NRS) pain score showed no significant difference, with a standardized mean difference (MD) of 0.23 (95% CI: −0.13 to 0.59, <i>p</i> = 0.21, <i>I</i><sup>2</sup> = 0%). For morphine milligram equivalent (MME), a meta-analysis of two studies (344 observations) resulted in an MD of −0.03 (95% CI: −0.09 to 0.04, <i>p</i> = 0.45, <i>I</i><sup>2</sup> = 97%). However, the side effects analysis from four studies (608 observations) showed a significantly higher relative risk (RR) of 5.74 (95% CI: 2.80–11.79, <i>p</i> &lt; 0.0001, <i>I</i><sup>2</sup> = 0%) for mild side effects, including nausea, vomiting, and dizziness.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Ketamine qualitative synthesis shows potential for improving pain management in SCD patients during VOC, but without statistically significant differences in pain reduction. It is associated with increased mild side effects, though no severe adverse events were reported. Further research is needed to increase the sample size and power of the analysis to clarify optimal dosing and administration protocols for ketamine in this context.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"5 6","pages":"1312-1321"},"PeriodicalIF":0.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647709/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real-world practice 一项关于FLT3抑制剂在急性髓性白血病治疗使用和反应率的GIMEMA调查:来自意大利现实世界实践的见解。
Pub Date : 2024-11-22 DOI: 10.1002/jha2.1045
Monica Messina, Alfonso Piciocchi, Leonardo M. Siena, Stefano Soddu, Francesco Buccisano, Cristina Mecucci, Giovanni Martinelli, Antonio Curti, Roberto Cairoli, Paola Fazi, Marco Vignetti, Maria Teresa Voso, Adriano Venditti, Anna Candoni

Given the limited data on the real-life therapeutic use of feline McDonough sarcoma (FMS)-like tyrosine kinase 3 (FLT3) inhibitors in Italy, we surveyed investigators at 59 Italian hematology centers to gain insight into the proportion of acute myeloid leukemia (AML) patients receiving FLT3 inhibitors and we collected data on the efficacy and safety of these agents. The survey results showed that in the real-life setting the response rate of the 3/7 + midostaurin regimen in newly diagnosed FLT3-mutated AML and of gilteritinib in the relapsed/refractory AML were comparable to that reported in the registrative clinical trials. The 3/7 + midostaurin treatment resulted in a 63% of complete remission (CR) rates and gilteritinib in a 44% of CR rates. The discontinuation rate of gilteritinib for intolerance or toxicity was low (accounting for 4% of treated cases).

鉴于意大利猫麦克多诺肉瘤(FMS)样酪氨酸激酶3 (FLT3)抑制剂在现实生活中的治疗应用数据有限,我们调查了意大利59个血液学中心的研究人员,以了解接受FLT3抑制剂的急性髓性白血病(AML)患者的比例,并收集了这些药物的疗效和安全性数据。调查结果显示,在现实环境中,3/7 + midoin方案对新诊断的flt3突变AML的反应率和吉特替尼方案对复发/难治性AML的反应率与注册临床试验报告的反应率相当。3/7 + midoin治疗导致63%的完全缓解(CR)率,吉特替尼导致44%的CR率。吉特替尼因不耐受或毒性而停药的比率很低(占治疗病例的4%)。
{"title":"A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real-world practice","authors":"Monica Messina,&nbsp;Alfonso Piciocchi,&nbsp;Leonardo M. Siena,&nbsp;Stefano Soddu,&nbsp;Francesco Buccisano,&nbsp;Cristina Mecucci,&nbsp;Giovanni Martinelli,&nbsp;Antonio Curti,&nbsp;Roberto Cairoli,&nbsp;Paola Fazi,&nbsp;Marco Vignetti,&nbsp;Maria Teresa Voso,&nbsp;Adriano Venditti,&nbsp;Anna Candoni","doi":"10.1002/jha2.1045","DOIUrl":"10.1002/jha2.1045","url":null,"abstract":"<p>Given the limited data on the real-life therapeutic use of feline McDonough sarcoma (FMS)-like tyrosine kinase 3 (FLT3) inhibitors in Italy, we surveyed investigators at 59 Italian hematology centers to gain insight into the proportion of acute myeloid leukemia (AML) patients receiving FLT3 inhibitors and we collected data on the efficacy and safety of these agents. The survey results showed that in the real-life setting the response rate of the 3/7 + midostaurin regimen in newly diagnosed FLT3-mutated AML and of gilteritinib in the relapsed/refractory AML were comparable to that reported in the registrative clinical trials. The 3/7 + midostaurin treatment resulted in a 63% of complete remission (CR) rates and gilteritinib in a 44% of CR rates. The discontinuation rate of gilteritinib for intolerance or toxicity was low (accounting for 4% of treated cases).</p>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"5 6","pages":"1274-1277"},"PeriodicalIF":0.0,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of secondary-type mutations in acute myeloid leukemia with CEBPA mutation 继发性突变对急性髓系白血病伴CEBPA突变的影响。
Pub Date : 2024-11-22 DOI: 10.1002/jha2.1055
Davidson Zhao, Musani Rumina, Mojgan Zarif, Cuihong Wei, Hong Chang
<p>To the Editor,</p><p>Secondary-type mutations (STM: <i>ASXL1</i>, <i>BCOR</i>, <i>EZH2</i>, <i>SF3B1</i>, <i>SRSF2</i>, <i>STAG2</i>, <i>U2AF1</i>, and <i>ZRSR2</i>) in acute myeloid leukemia (AML) were reported to be highly specific for secondary disease and associated with inferior event-free survival (EFS) [<span>1, 2</span>]. In light of these findings, the newly-revised 5th edition of the WHO Classification of Haematolymphoid Tumours (WHO-HAEM5) includes STM in the criteria defining AML, myelodysplasia-related (AML-MR) [<span>3</span>]. In the newly-published International Consensus of Classification of myeloid neoplasms and acute leukemia (ICC), <i>RUNX1</i> mutation together with STM as described by WHO-HAEM5 define the entity of AML with myelodysplasia-related gene mutations [<span>4</span>]. To date, several studies have examined the impact of STM in other molecularly defined entities of AML such as <i>NPM1</i>+ AML [<span>5-9</span>]. However, the impact of STM in AML with <i>CEBPA</i> mutation has not been studied extensively and remains unclear. Thus, we sought to investigate the clinical impact of STM in AML with <i>CEBPA</i> mutation.</p><p>We conducted a retrospective analysis with a single center cohort of 38 cases of AML with <i>CEBPA</i> mutation diagnosed at our institution from 2015 to 2024. Patients were included if they met WHO-HAEM5 criteria of blasts ≥ 20% and either biallelic <i>CEBPA</i> mutation or single <i>CEBPA</i> mutation in the basic leucine zipper (bZIP) domain. Cytogenetic testing, molecular genetic testing, and variant calling in next-generation sequencing were performed according to previously described procedures [<span>10</span>]. Gene panel for targeted sequencing and exon coverage for hotspot genes are listed in Tables S1 and S2.</p><p>The baseline clinicopathological characteristics and co-mutation landscape of the study cohort are summarized in Table 1 and Figure 1A. Of the 38 patients with AML with <i>CEBPA</i> mutation, 11 (29%) had STM. <i>SRSF2</i> and <i>STAG2</i> were the most common STMs (both 8/38, 21%), followed by <i>ASXL1</i> (6/38, 16%), <i>BCOR</i> (2/38, 5%), and <i>U2AF1</i> (1/38, 3%). <i>RUNX1</i> mutations were found in two (5%) patients, both of whom had concurrent WHO-HAEM5-defined STMs. <i>EZH2</i>, <i>ZRSR2</i>, and <i>SF3B1</i> mutations were not detected. The most common recurrent (>10%) co-mutated genes in the cohort were <i>TET2</i> (10/38; 26%), <i>GATA2</i> (9/38, 24%), <i>WT1</i> (8/38, 21%), <i>NRAS</i> (6/38, 16%) and <i>FLT3</i>-ITD (4/38, 11%). Compared to patients without STM, patients with STM were older, had less proliferative disease, had lower hemoglobin levels, and had significantly lower variant allele frequency of mutant <i>CEBPA</i> and infrequent in-frame bZIP <i>CEBPA</i> mutation.</p><p>Consistent with the older age of the STM+ group, only five (46%) patients received intensive chemotherapy compared to all 27 (100%) patients in the STM-ve group. Of note,
未来需要更大队列的前瞻性研究来证实STM或框架内bZIP突变是否对并发STM和CEBPA突变的AML患者具有预后意义。总之,我们的数据表明,WHO-HAEM5定义的伴有CEBPA突变并并发STM的AML患者可能更适合归类为AML- mr。根据ICC分类,它只选择帧内bZIP CEBPA突变,识别无STM的同质队列,并有效排除可能更好地归类为AML-MR的患者。Davidson Zhao收集并分析了数据并撰写了手稿。Musani Rumina收集数据并撰写手稿。Mojgan Zarif和Cuihong Wei收集了数据。洪昌设计了这项研究并分析了数据。所有作者阅读,严格审查,并批准了手稿。作者声明无利益冲突。作者没有得到这项工作的特别资助。作者已确认本次提交不需要伦理批准声明。作者已确认本次提交不需要患者同意声明。作者已确认该提交不需要临床试验注册。
{"title":"Impact of secondary-type mutations in acute myeloid leukemia with CEBPA mutation","authors":"Davidson Zhao,&nbsp;Musani Rumina,&nbsp;Mojgan Zarif,&nbsp;Cuihong Wei,&nbsp;Hong Chang","doi":"10.1002/jha2.1055","DOIUrl":"10.1002/jha2.1055","url":null,"abstract":"&lt;p&gt;To the Editor,&lt;/p&gt;&lt;p&gt;Secondary-type mutations (STM: &lt;i&gt;ASXL1&lt;/i&gt;, &lt;i&gt;BCOR&lt;/i&gt;, &lt;i&gt;EZH2&lt;/i&gt;, &lt;i&gt;SF3B1&lt;/i&gt;, &lt;i&gt;SRSF2&lt;/i&gt;, &lt;i&gt;STAG2&lt;/i&gt;, &lt;i&gt;U2AF1&lt;/i&gt;, and &lt;i&gt;ZRSR2&lt;/i&gt;) in acute myeloid leukemia (AML) were reported to be highly specific for secondary disease and associated with inferior event-free survival (EFS) [&lt;span&gt;1, 2&lt;/span&gt;]. In light of these findings, the newly-revised 5th edition of the WHO Classification of Haematolymphoid Tumours (WHO-HAEM5) includes STM in the criteria defining AML, myelodysplasia-related (AML-MR) [&lt;span&gt;3&lt;/span&gt;]. In the newly-published International Consensus of Classification of myeloid neoplasms and acute leukemia (ICC), &lt;i&gt;RUNX1&lt;/i&gt; mutation together with STM as described by WHO-HAEM5 define the entity of AML with myelodysplasia-related gene mutations [&lt;span&gt;4&lt;/span&gt;]. To date, several studies have examined the impact of STM in other molecularly defined entities of AML such as &lt;i&gt;NPM1&lt;/i&gt;+ AML [&lt;span&gt;5-9&lt;/span&gt;]. However, the impact of STM in AML with &lt;i&gt;CEBPA&lt;/i&gt; mutation has not been studied extensively and remains unclear. Thus, we sought to investigate the clinical impact of STM in AML with &lt;i&gt;CEBPA&lt;/i&gt; mutation.&lt;/p&gt;&lt;p&gt;We conducted a retrospective analysis with a single center cohort of 38 cases of AML with &lt;i&gt;CEBPA&lt;/i&gt; mutation diagnosed at our institution from 2015 to 2024. Patients were included if they met WHO-HAEM5 criteria of blasts ≥ 20% and either biallelic &lt;i&gt;CEBPA&lt;/i&gt; mutation or single &lt;i&gt;CEBPA&lt;/i&gt; mutation in the basic leucine zipper (bZIP) domain. Cytogenetic testing, molecular genetic testing, and variant calling in next-generation sequencing were performed according to previously described procedures [&lt;span&gt;10&lt;/span&gt;]. Gene panel for targeted sequencing and exon coverage for hotspot genes are listed in Tables S1 and S2.&lt;/p&gt;&lt;p&gt;The baseline clinicopathological characteristics and co-mutation landscape of the study cohort are summarized in Table 1 and Figure 1A. Of the 38 patients with AML with &lt;i&gt;CEBPA&lt;/i&gt; mutation, 11 (29%) had STM. &lt;i&gt;SRSF2&lt;/i&gt; and &lt;i&gt;STAG2&lt;/i&gt; were the most common STMs (both 8/38, 21%), followed by &lt;i&gt;ASXL1&lt;/i&gt; (6/38, 16%), &lt;i&gt;BCOR&lt;/i&gt; (2/38, 5%), and &lt;i&gt;U2AF1&lt;/i&gt; (1/38, 3%). &lt;i&gt;RUNX1&lt;/i&gt; mutations were found in two (5%) patients, both of whom had concurrent WHO-HAEM5-defined STMs. &lt;i&gt;EZH2&lt;/i&gt;, &lt;i&gt;ZRSR2&lt;/i&gt;, and &lt;i&gt;SF3B1&lt;/i&gt; mutations were not detected. The most common recurrent (&gt;10%) co-mutated genes in the cohort were &lt;i&gt;TET2&lt;/i&gt; (10/38; 26%), &lt;i&gt;GATA2&lt;/i&gt; (9/38, 24%), &lt;i&gt;WT1&lt;/i&gt; (8/38, 21%), &lt;i&gt;NRAS&lt;/i&gt; (6/38, 16%) and &lt;i&gt;FLT3&lt;/i&gt;-ITD (4/38, 11%). Compared to patients without STM, patients with STM were older, had less proliferative disease, had lower hemoglobin levels, and had significantly lower variant allele frequency of mutant &lt;i&gt;CEBPA&lt;/i&gt; and infrequent in-frame bZIP &lt;i&gt;CEBPA&lt;/i&gt; mutation.&lt;/p&gt;&lt;p&gt;Consistent with the older age of the STM+ group, only five (46%) patients received intensive chemotherapy compared to all 27 (100%) patients in the STM-ve group. Of note,","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"5 6","pages":"1370-1372"},"PeriodicalIF":0.0,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immediate improvement in patient care: Auditing adherence to the British Society for Haematology guidelines on screening and management of the long-term consequences of multiple myeloma and treatment 患者护理的即时改善:审计遵守英国血液病学会关于多发性骨髓瘤和治疗的长期后果的筛查和管理指南。
Pub Date : 2024-11-15 DOI: 10.1002/jha2.999
Kerrie Sweeney, Aaron Niblock, Diana Greenfield, John Snowden

Advances in myeloma have resulted in improved prognosis for patients. However complications of the disease and treatment, pose a risk of specific long-term consequences. An audit tool was adapted to assess adherence to the British Society for Haematology guidelines for screening and management of long-term myeloma consequences. Thereafter a screening checklist was developed to prompt the implementation of guideline recommendations, followed by a re-audit evaluating the effectiveness of the checklist.

Good baseline practice was identified relating to vaccinations, herpes prophylaxis, dental assessment, bisphosphonates, calcium/ vitamin D supplementation and holistic needs assessments. However gaps in practice included monitoring of lipids, HBA1C, NT-pro-BNP/ BNP, BMI, calcium/ vitamin D and parathyroid hormone in kidney disease, endocrine screening and geriatric assessments. Re-audit demonstrated that geriatric assessment remains a gap in practice, however other standards now scored between 80 to 100% compliance, highlighting the benefits of a screening checklist, to increase adherence to recommendations.

骨髓瘤的进展改善了患者的预后。然而,该病的并发症和治疗可能造成特定的长期后果。采用一种审计工具来评估英国血液病学会筛查和管理骨髓瘤长期后果指南的依从性。此后,制定了一份筛选清单,以促进指南建议的实施,随后进行了重新审核,评估清单的有效性。确定了与疫苗接种、疱疹预防、牙科评估、双膦酸盐、钙/维生素D补充和整体需求评估有关的良好基线做法。然而,实践中的差距包括监测血脂、HBA1C、NT-pro-BNP/ BNP、BMI、钙/维生素D和甲状旁腺激素在肾脏疾病、内分泌筛查和老年评估中的作用。重新审计表明,老年评估在实践中仍然存在差距,但其他标准的符合性现在在80%至100%之间,突出了筛查清单的好处,以增加对建议的遵守。
{"title":"Immediate improvement in patient care: Auditing adherence to the British Society for Haematology guidelines on screening and management of the long-term consequences of multiple myeloma and treatment","authors":"Kerrie Sweeney,&nbsp;Aaron Niblock,&nbsp;Diana Greenfield,&nbsp;John Snowden","doi":"10.1002/jha2.999","DOIUrl":"10.1002/jha2.999","url":null,"abstract":"<p>Advances in myeloma have resulted in improved prognosis for patients. However complications of the disease and treatment, pose a risk of specific long-term consequences. An audit tool was adapted to assess adherence to the British Society for Haematology guidelines for screening and management of long-term myeloma consequences. Thereafter a screening checklist was developed to prompt the implementation of guideline recommendations, followed by a re-audit evaluating the effectiveness of the checklist.</p><p>Good baseline practice was identified relating to vaccinations, herpes prophylaxis, dental assessment, bisphosphonates, calcium/ vitamin D supplementation and holistic needs assessments. However gaps in practice included monitoring of lipids, HBA1C, NT-pro-BNP/ BNP, BMI, calcium/ vitamin D and parathyroid hormone in kidney disease, endocrine screening and geriatric assessments. Re-audit demonstrated that geriatric assessment remains a gap in practice, however other standards now scored between 80 to 100% compliance, highlighting the benefits of a screening checklist, to increase adherence to recommendations.</p>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"5 6","pages":"1359-1362"},"PeriodicalIF":0.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between microenvironment-related genes and prognosis of primary central nervous system lymphoma 微环境相关基因与原发性中枢神经系统淋巴瘤预后的关系
Pub Date : 2024-11-14 DOI: 10.1002/jha2.1046
Keiichiro Hattori, Kenichi Makishima, Sakurako Suma, Yoshiaki Abe, Yasuhito Suehara, Tatsuhiro Sakamoto, Naoki Kurita, Ryota Ishii, Ryota Matsuoka, Masahide Matsuda, Takao Tsurubuchi, Ryo Nishikawa, Shota Tanaka, Akitake Mukasa, Yoshitaka Narita, Koichi Ichimura, Motoo Nagane, Shingo Takano, Bryan J. Mathis, Eiichi Ishikawa, Daisuke Matsubara, Shigeru Chiba, Mamiko Sakata-Yanagimoto

Background

Primary central nervous system lymphoma (PCNSL) is a rare lymphoid malignancy. Systemic profiling of the PCNSL tumor microenvironment (TME) was previously conducted through gene expression analysis. We investigated the prognostic impact of TME on survival to establish novel prognostic biomarkers in PCNSL patients.

Methods

We analyzed expression levels of 770 neuroinflammation-related (NFR) genes via NanoString nCounter technology in tumor samples from 30 PCNSL patients. Genes related to the “recurrence group (RG)” or “non-recurrence group (NRG)” were identified and validated using whole transcriptomic analysis of an independent PCNSL cohort (n = 30).

Results

Forty-five of 770 NFR genes were highly expressed in the RG (3-year overall survival (OS, 22.2%), compared with the NRG group (3-year OS 66.7%). Signatures related to glial cells were enriched in the RG-associated gene set. Multivariate analysis revealed that high expressions of TUBB4A (p = 0.028, HR: 3.88), S100B (p = 0.046, HR: 3.093), and SLC6A1 (p = 0.034, HR: 3.765) were significantly related to death. Expression levels of these three genes were also significantly associated with poor OS in the validation cohort. Immunohistochemical staining against TUBB4A, S100B, and proteins specific to glial cells (GFAP, OLIG2, and CD68) revealed significantly higher positivity in RG glial cells.

Conclusion

These data suggest that TME-related genes play a crucial role in the pathogenesis of PCNSL, complementing the well-known involvement of the NF-kB signaling pathway. TME targeting, especially glial cell-specific proteins, may thus open new and complementary avenues of therapy for all stages of PCNSL.

背景:原发性中枢神经系统淋巴瘤(PCNSL)是一种罕见的淋巴系统恶性肿瘤。PCNSL肿瘤微环境(TME)的系统分析以前是通过基因表达分析进行的。我们研究了TME对PCNSL患者生存的预后影响,以建立新的预后生物标志物。方法:通过NanoString nCounter技术分析了30例PCNSL患者肿瘤样本中770个神经炎症相关(NFR)基因的表达水平。通过独立PCNSL队列(n = 30)的全转录组分析,鉴定并验证了与“复发组(RG)”或“非复发组(NRG)”相关的基因。结果:770个NFR基因中有45个在RG组中高表达(3年总生存率为22.2%),而NRG组的3年总生存率为66.7%。rg相关基因集中富集了与胶质细胞相关的特征。多因素分析显示,TUBB4A (p = 0.028, HR: 3.88)、S100B (p = 0.046, HR: 3.093)、SLC6A1 (p = 0.034, HR: 3.765)的高表达与死亡显著相关。在验证队列中,这三个基因的表达水平也与不良OS显著相关。免疫组化对TUBB4A、S100B和胶质细胞特异性蛋白(GFAP、OLIG2和CD68)的免疫组化染色显示RG胶质细胞中明显较高的阳性。结论:这些数据表明,tme相关基因在PCNSL的发病机制中起着至关重要的作用,补充了众所周知的NF-kB信号通路的参与。因此,TME靶向,特别是胶质细胞特异性蛋白,可能为PCNSL的所有阶段开辟新的和互补的治疗途径。
{"title":"Association between microenvironment-related genes and prognosis of primary central nervous system lymphoma","authors":"Keiichiro Hattori,&nbsp;Kenichi Makishima,&nbsp;Sakurako Suma,&nbsp;Yoshiaki Abe,&nbsp;Yasuhito Suehara,&nbsp;Tatsuhiro Sakamoto,&nbsp;Naoki Kurita,&nbsp;Ryota Ishii,&nbsp;Ryota Matsuoka,&nbsp;Masahide Matsuda,&nbsp;Takao Tsurubuchi,&nbsp;Ryo Nishikawa,&nbsp;Shota Tanaka,&nbsp;Akitake Mukasa,&nbsp;Yoshitaka Narita,&nbsp;Koichi Ichimura,&nbsp;Motoo Nagane,&nbsp;Shingo Takano,&nbsp;Bryan J. Mathis,&nbsp;Eiichi Ishikawa,&nbsp;Daisuke Matsubara,&nbsp;Shigeru Chiba,&nbsp;Mamiko Sakata-Yanagimoto","doi":"10.1002/jha2.1046","DOIUrl":"10.1002/jha2.1046","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Primary central nervous system lymphoma (PCNSL) is a rare lymphoid malignancy. Systemic profiling of the PCNSL tumor microenvironment (TME) was previously conducted through gene expression analysis. We investigated the prognostic impact of TME on survival to establish novel prognostic biomarkers in PCNSL patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We analyzed expression levels of 770 neuroinflammation-related (NFR) genes via NanoString nCounter technology in tumor samples from 30 PCNSL patients. Genes related to the “recurrence group (RG)” or “non-recurrence group (NRG)” were identified and validated using whole transcriptomic analysis of an independent PCNSL cohort (<i>n</i> = 30).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Forty-five of 770 NFR genes were highly expressed in the RG (3-year overall survival (OS, 22.2%), compared with the NRG group (3-year OS 66.7%). Signatures related to glial cells were enriched in the RG-associated gene set. Multivariate analysis revealed that high expressions of <i>TUBB4A</i> (<i>p</i> = 0.028, HR: 3.88), <i>S100B</i> (<i>p</i> = 0.046, HR: 3.093), and <i>SLC6A1</i> (<i>p</i> = 0.034, HR: 3.765) were significantly related to death. Expression levels of these three genes were also significantly associated with poor OS in the validation cohort. Immunohistochemical staining against TUBB4A, S100B, and proteins specific to glial cells (GFAP, OLIG2, and CD68) revealed significantly higher positivity in RG glial cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These data suggest that TME-related genes play a crucial role in the pathogenesis of PCNSL, complementing the well-known involvement of the NF-kB signaling pathway. TME targeting, especially glial cell-specific proteins, may thus open new and complementary avenues of therapy for all stages of PCNSL.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"5 6","pages":"1201-1214"},"PeriodicalIF":0.0,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Congestive heart failure after anthracycline-containing treatment for Hodgkin lymphoma: A Swedish matched cohort study 含蒽环类药物治疗霍奇金淋巴瘤后充血性心力衰竭:瑞典匹配队列研究。
Pub Date : 2024-11-13 DOI: 10.1002/jha2.1048
Joachim Baech, Tarec Christoffer El-Galaly, Joshua P. Entrop, Ingrid Glimelius, Daniel Molin, Sissel Johanne Godtfredsen, Michael J. Crowther, Karin E. Smedby, Sandra Eloranta, Caroline E. Dietrich

Introduction

Congestive heart failure (CHF) is a known complication after anthracyclines and radiotherapy for classical Hodgkin lymphoma (cHL). Contemporary cHL treatment may be associated with less risk because radiotherapy use and techniques have changed substantially over time.

Methods

In this study, Swedish cHL patients diagnosed in 2000–2018, and treated with adriamycin [doxorubicin], bleomycin, vinblastine, and dacarbazine (ABVD) or bleomycin, etoposide, Adriamycin [doxorubicin], cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP), were matched 1:10 to the general population on birth year and sex to investigate relative rates and cumulative risks of CHF.

Results

A total of 1994 cHL patients were included, with a median age of 34 years. The median follow-up was 8.1 years. The CHF rate was higher for patients versus comparators (adjusted hazard ratio [HR] = 3.02, 95% confidence interval [CI]: 2.26–4.02). Patients treated with ≤200 mg/m2 of anthracyclines had HR of 2.89 (95% CI: 1.51–3.47) versus 3.91 (95% CI: 2.72–5.60) for >200 mg/m2. Treatment with ABVD was associated with a significantly higher CHF rate (adjusted HR = 3.25, 95% CI: 2.31–4.23), while BEACOPP was not (adjusted HR = 1.95, 95% CI: 0.91–4.16). The increase in relative rates translated to the absolute scale, with an increased risk persisting up to 18 years for low cumulative doses.

Conclusion

These findings highlight that cHL survivors still face a substantial excess risk of CHF in the modern treatment era and that focus on cardiovascular health remains relevant.

简介:充血性心力衰竭(CHF)是蒽环类药物和放射治疗经典霍奇金淋巴瘤(cHL)后的已知并发症。由于放疗的使用和技术随着时间的推移发生了很大的变化,当代cHL治疗的风险可能较低。方法:在本研究中,2000-2018年诊断为cHL并接受阿霉素[阿霉素]、博来霉素、长春碱和达卡巴嗪(ABVD)或博来霉素、乙泊苷、阿霉素[阿霉素]、环磷酰胺、长春新碱、丙卡嗪和泼尼松(BEACOPP)治疗的瑞典cHL患者,按出生年和性别与普通人群进行1:10匹配,调查CHF的相对发病率和累积风险。结果:共纳入cHL患者1994例,中位年龄34岁。中位随访时间为8.1年。患者的CHF发生率高于对照组(校正风险比[HR] = 3.02, 95%可信区间[CI]: 2.26-4.02)。≤200mg /m2蒽环类药物组患者的风险比为2.89 (95% CI: 1.51-3.47),而≤200mg /m2组患者的风险比为3.91 (95% CI: 2.72-5.60)。ABVD治疗与较高的CHF发生率相关(调整后的HR = 3.25, 95% CI: 2.31-4.23),而BEACOPP治疗与此无关(调整后的HR = 1.95, 95% CI: 0.91-4.16)。相对比率的增加转化为绝对规模,低累积剂量的风险增加可持续18年。结论:这些发现强调,在现代治疗时代,cHL幸存者仍然面临大量的CHF超额风险,关注心血管健康仍然是相关的。
{"title":"Congestive heart failure after anthracycline-containing treatment for Hodgkin lymphoma: A Swedish matched cohort study","authors":"Joachim Baech,&nbsp;Tarec Christoffer El-Galaly,&nbsp;Joshua P. Entrop,&nbsp;Ingrid Glimelius,&nbsp;Daniel Molin,&nbsp;Sissel Johanne Godtfredsen,&nbsp;Michael J. Crowther,&nbsp;Karin E. Smedby,&nbsp;Sandra Eloranta,&nbsp;Caroline E. Dietrich","doi":"10.1002/jha2.1048","DOIUrl":"10.1002/jha2.1048","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Congestive heart failure (CHF) is a known complication after anthracyclines and radiotherapy for classical Hodgkin lymphoma (cHL). Contemporary cHL treatment may be associated with less risk because radiotherapy use and techniques have changed substantially over time.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this study, Swedish cHL patients diagnosed in 2000–2018, and treated with adriamycin [doxorubicin], bleomycin, vinblastine, and dacarbazine (ABVD) or bleomycin, etoposide, Adriamycin [doxorubicin], cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP), were matched 1:10 to the general population on birth year and sex to investigate relative rates and cumulative risks of CHF.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 1994 cHL patients were included, with a median age of 34 years. The median follow-up was 8.1 years. The CHF rate was higher for patients versus comparators (adjusted hazard ratio [HR] = 3.02, 95% confidence interval [CI]: 2.26–4.02). Patients treated with ≤200 mg/m<sup>2</sup> of anthracyclines had HR of 2.89 (95% CI: 1.51–3.47) versus 3.91 (95% CI: 2.72–5.60) for &gt;200 mg/m<sup>2</sup>. Treatment with ABVD was associated with a significantly higher CHF rate (adjusted HR = 3.25, 95% CI: 2.31–4.23), while BEACOPP was not (adjusted HR = 1.95, 95% CI: 0.91–4.16). The increase in relative rates translated to the absolute scale, with an increased risk persisting up to 18 years for low cumulative doses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These findings highlight that cHL survivors still face a substantial excess risk of CHF in the modern treatment era and that focus on cardiovascular health remains relevant.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"5 6","pages":"1190-1200"},"PeriodicalIF":0.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647705/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New insights into the mechanisms of red blood cell enucleation: From basics to clinical applications 红细胞去核机制的新见解:从基础知识到临床应用。
Pub Date : 2024-11-13 DOI: 10.1002/jha2.1051
Qianli Zhuo, Zhaojun Zhang, Xiangdong Fang

Background

Red blood cell (RBC) enucleation is a crucial step in the process of erythropoiesis. By removing the nucleus, RBCs gain greater flexibility, enabling them to traverse narrow capillaries with ease, thereby enhancing the efficiency of oxygen and carbon dioxide transport. This transformation underscores the intricate balance between cellular structure and function essential for maintaining homeostasis.

Topic

This review delves into the multifaceted enucleation process, outlining its complex steps that encompass protein sorting, vesicle trafficking, cytoskeletal remodeling, and apoptosis regulation, while also exploring the potential of enhancing the enucleation rate of RBCs in vitro. We emphasize the intricate regulation of this process, which is orchestrated by multiple factors. This includes transcription factors that meticulously guide protein synthesis and sorting through the modulation of gene expression, as well as non-coding RNAs that play a pivotal role in post-transcriptional regulation during various stages of RBC enucleation. Additionally, macrophages participate in the enucleation process by engulfing and clearing the extruded nuclei, further ensuring the proper development of RBCs. Although many studies have deeply explored the molecular mechanisms of enucleation, the roles of apoptosis and anti-apoptotic processes in RBC enucleation remain incompletely understood.

Implication

In this review, we aim to comprehensively summarize the RBC enucleation process and explore the progress made in ex vivo RBC generation. In the future, a deeper understanding of the enucleation process could provide significant benefits to patients suffering from anemia and other related conditions.

背景:红细胞去核是红细胞生成过程中至关重要的一步。通过去除细胞核,红细胞获得更大的灵活性,使它们能够轻松地穿过狭窄的毛细血管,从而提高氧气和二氧化碳运输的效率。这种转变强调了维持体内平衡所必需的细胞结构和功能之间的复杂平衡。主题:本综述深入探讨了红细胞去核的多方面过程,概述了其复杂的步骤,包括蛋白质分选、囊泡运输、细胞骨架重塑和凋亡调节,同时也探讨了体外提高红细胞去核率的潜力。我们强调这一过程的复杂调节,这是由多种因素精心策划的。这包括通过基因表达的调节精心引导蛋白质合成和分类的转录因子,以及在红细胞去核的各个阶段在转录后调控中起关键作用的非编码rna。此外,巨噬细胞通过吞噬和清除挤压的细胞核参与去核过程,进一步保证红细胞的正常发育。虽然许多研究深入探讨了去核的分子机制,但凋亡和抗凋亡过程在红细胞去核中的作用仍不完全清楚。在这篇综述中,我们旨在全面总结红细胞去核过程,并探讨体外红细胞生成的进展。在未来,对去核过程的更深入了解可以为患有贫血和其他相关疾病的患者提供重大益处。
{"title":"New insights into the mechanisms of red blood cell enucleation: From basics to clinical applications","authors":"Qianli Zhuo,&nbsp;Zhaojun Zhang,&nbsp;Xiangdong Fang","doi":"10.1002/jha2.1051","DOIUrl":"10.1002/jha2.1051","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Red blood cell (RBC) enucleation is a crucial step in the process of erythropoiesis. By removing the nucleus, RBCs gain greater flexibility, enabling them to traverse narrow capillaries with ease, thereby enhancing the efficiency of oxygen and carbon dioxide transport. This transformation underscores the intricate balance between cellular structure and function essential for maintaining homeostasis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Topic</h3>\u0000 \u0000 <p>This review delves into the multifaceted enucleation process, outlining its complex steps that encompass protein sorting, vesicle trafficking, cytoskeletal remodeling, and apoptosis regulation, while also exploring the potential of enhancing the enucleation rate of RBCs in vitro. We emphasize the intricate regulation of this process, which is orchestrated by multiple factors. This includes transcription factors that meticulously guide protein synthesis and sorting through the modulation of gene expression, as well as non-coding RNAs that play a pivotal role in post-transcriptional regulation during various stages of RBC enucleation. Additionally, macrophages participate in the enucleation process by engulfing and clearing the extruded nuclei, further ensuring the proper development of RBCs. Although many studies have deeply explored the molecular mechanisms of enucleation, the roles of apoptosis and anti-apoptotic processes in RBC enucleation remain incompletely understood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Implication</h3>\u0000 \u0000 <p>In this review, we aim to comprehensively summarize the RBC enucleation process and explore the progress made in ex vivo RBC generation. In the future, a deeper understanding of the enucleation process could provide significant benefits to patients suffering from anemia and other related conditions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"5 6","pages":"1301-1311"},"PeriodicalIF":0.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Isolated thrombocytopenia in pregnancy: A monocentric retrospective study of 63 pregnancies in 59 women 妊娠期孤立性血小板减少症:一项对59名妇女63例妊娠的单中心回顾性研究。
Pub Date : 2024-11-08 DOI: 10.1002/jha2.957
Giulia Freddi, Enea Parimbelli, Federico Vai, Silvana Quaglini, Valeria Bozzi, Serena Barozzi, Fausta Beneventi, Irene De Maggio, Chiara Cavagnoli, Antonio Di Sabatino, Patrizia Noris, Federica Melazzini

Thrombocytopenia during pregnancy is often thought to be associated with severe bleeding manifestations. Three are the main disorders associated with this condition: gestational thrombocytopenia (GT), immune thrombocytopenia (ITP), and inherited thrombocytopenias (ITs). Reaching the correct diagnosis of this condition has relevant therapeutic and outcome implications. We performed a retrospective, observational, monocentric study enrolling 59 consecutive women with isolated thrombocytopenia, attended to our referral center in the last 3 years. Together with personal and family history, platelet (PLT) count trend and mean platelet volume (MPV) in pregnancy are helpful for the diagnosis, with the highest PLT count in GT and lowest in ITs, with different timing of count decrease. MPV is significantly increased in both ITs and ITP. Misdiagnosis with ITP was responsible for unnecessary and unsuccessful therapy in some GT or ITs pregnant women, determining relevant side effects. Excluding inherited platelet function disorders (IPFDs), the bleeding risk for mother with thrombocytopenia and their newborns is similar to the general population. Vaginal delivery is associated with a lower risk of bleeding than cesarean section and therefore is preferable whenever obstetrical–gynecological conditions permit.

妊娠期血小板减少常被认为与严重出血表现有关。与此相关的主要疾病有三种:妊娠性血小板减少症(GT)、免疫性血小板减少症(ITP)和遗传性血小板减少症(ITs)。对这种疾病的正确诊断具有相关的治疗和预后意义。我们进行了一项回顾性、观察性、单中心研究,纳入了过去3年内在我们转诊中心就诊的59例连续的孤立性血小板减少症女性患者。妊娠期血小板(PLT)计数趋势及平均血小板体积(MPV),结合个人及家族史对诊断有帮助,血小板计数在GT期最高,在ITs期最低,且血小板计数减少的时间不同。ITs和ITP的MPV均显著升高。误诊ITP是部分GT或ITs孕妇治疗不必要和不成功的原因,确定了相关的副作用。排除遗传性血小板功能障碍(ipfd),母亲与血小板减少及其新生儿的出血风险与一般人群相似。阴道分娩比剖宫产出血的风险更低,因此在妇产科条件允许的情况下更可取。
{"title":"Isolated thrombocytopenia in pregnancy: A monocentric retrospective study of 63 pregnancies in 59 women","authors":"Giulia Freddi,&nbsp;Enea Parimbelli,&nbsp;Federico Vai,&nbsp;Silvana Quaglini,&nbsp;Valeria Bozzi,&nbsp;Serena Barozzi,&nbsp;Fausta Beneventi,&nbsp;Irene De Maggio,&nbsp;Chiara Cavagnoli,&nbsp;Antonio Di Sabatino,&nbsp;Patrizia Noris,&nbsp;Federica Melazzini","doi":"10.1002/jha2.957","DOIUrl":"10.1002/jha2.957","url":null,"abstract":"<p>Thrombocytopenia during pregnancy is often thought to be associated with severe bleeding manifestations. Three are the main disorders associated with this condition: gestational thrombocytopenia (GT), immune thrombocytopenia (ITP), and inherited thrombocytopenias (ITs). Reaching the correct diagnosis of this condition has relevant therapeutic and outcome implications. We performed a retrospective, observational, monocentric study enrolling 59 consecutive women with isolated thrombocytopenia, attended to our referral center in the last 3 years. Together with personal and family history, platelet (PLT) count trend and mean platelet volume (MPV) in pregnancy are helpful for the diagnosis, with the highest PLT count in GT and lowest in ITs, with different timing of count decrease. MPV is significantly increased in both ITs and ITP. Misdiagnosis with ITP was responsible for unnecessary and unsuccessful therapy in some GT or ITs pregnant women, determining relevant side effects. Excluding inherited platelet function disorders (IPFDs), the bleeding risk for mother with thrombocytopenia and their newborns is similar to the general population. Vaginal delivery is associated with a lower risk of bleeding than cesarean section and therefore is preferable whenever obstetrical–gynecological conditions permit.</p>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"5 6","pages":"1125-1132"},"PeriodicalIF":0.0,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Circulating tumor DNA for monitoring classic Hodgkin lymphoma patients: Correlation with FDG-PET/CT 修正:循环肿瘤DNA监测经典霍奇金淋巴瘤患者:与FDG-PET/CT的相关性。
Pub Date : 2024-11-04 DOI: 10.1002/jha2.1044

EJHaem. 2024 Feb; 5(1): 70–75.

The authors regret that the Acknowledgments section contains a mistake in the reference to the funding by the “Instituto de Salud Carlos III (ISCIII)” in the published article.

The correct reference is “This work was supported by Instituto de Salud Carlos III (ISCIII), projects PI19/00083 and PI22/00556 (co-funded by the European Union)”.

The authors would like to apologize for any inconvenience caused.

[这更正了文章DOI: 10.1002/jha2.826.]。
{"title":"Correction to: Circulating tumor DNA for monitoring classic Hodgkin lymphoma patients: Correlation with FDG-PET/CT","authors":"","doi":"10.1002/jha2.1044","DOIUrl":"10.1002/jha2.1044","url":null,"abstract":"<p>EJHaem. 2024 Feb; 5(1): 70–75.</p><p>The authors regret that the Acknowledgments section contains a mistake in the reference to the funding by the “Instituto de Salud Carlos III (ISCIII)” in the published article.</p><p>The correct reference is “This work was supported by Instituto de Salud Carlos III (ISCIII), projects PI19/00083 and PI22/00556 (co-funded by the European Union)”.</p><p>The authors would like to apologize for any inconvenience caused.</p>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"5 6","pages":"1373"},"PeriodicalIF":0.0,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fluctuation of physical function during chimeric antigen receptor T-cell therapy during rehabilitation intervention: Real-world data and risk factor analyses 康复干预期间嵌合抗原受体t细胞治疗期间身体功能的波动:真实世界数据和危险因素分析。
Pub Date : 2024-11-04 DOI: 10.1002/jha2.1043
Ryota Hamada, Yasuyuki Arai, Toshio Kitawaki, Naokazu Nakamura, Masanobu Murao, Michiko Matsushita, Junsuke Miyasaka, Tsugumi Asano, Tomoyasu Jo, Momoko Nishikori, Junya Kanda, Chisaki Mizumoto, Kouhei Yamashita, Ryosuke Ikeguchi, Akifumi Takaori-Kondo

Introduction

Patients undergoing chimeric antigen receptor (CAR) T-cell therapy face prolonged treatment timelines and are prone to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) after infusion. Disabilities in physical function and the importance of rehabilitation during CAR-T-cell therapy to maintain physical function have been poorly documented.

Method

We performed a retrospective cohort study to assess changes in exercise tolerance via differences in a 6-min-walking distance (Δ6MWD) and factors influencing it.

Results

A total of 77 patients who underwent rehabilitation during CAR-T-cell therapy were enrolled, and their 6MWD was 450 m (median, range 180–705 m) before and 450.5 m (107.0–735.0 m) 30 days after CAR-T treatment. No significant alteration in Δ6MWD was observed overall (11.0 m, 95% confidence interval, −56.1 to 88.2 m). Multiple regression analyses indicated that age (over vs. under 65 years) revealed no notable differences in Δ6MWD (20 vs. 10 m), while ΔHb (β = 0.24, p = 0.03), moderate/severe CRS (grade 1 with continuous fever or grade ≥2; β = −0.25, p = 0.03), and ICANS (any grade; β = −0.22, p = 0.04) were significantly associated with lower Δ6MWD.

Conclusion

This real-world study indicated that CAR-T-cell therapy is less likely to reduce physical function even in older patients if rehabilitation is properly performed, whereas CRS and ICANS can be risk factors to deprive exercise tolerance.

导语:接受CAR - t细胞治疗的患者面临治疗时间延长,输注后容易发生细胞因子释放综合征(CRS)和免疫效应细胞相关神经毒性综合征(ICANS)。身体功能障碍和car - t细胞治疗期间康复对维持身体功能的重要性文献很少。方法:我们进行了一项回顾性队列研究,通过6分钟步行距离(Δ6MWD)的差异评估运动耐量的变化及其影响因素。结果:共纳入77例CAR-T细胞治疗期间康复的患者,其6MWD在CAR-T治疗前为450 m(中位数,180-705 m),在CAR-T治疗后30天为450.5 m (107.0-735.0 m)。总体上Δ6MWD无显著变化(11.0 m, 95%可信区间,-56.1 ~ 88.2 m)。多元回归分析显示年龄(65岁以上vs. 65岁以下)Δ6MWD无显著差异(20 vs. 10 m),而ΔHb (β = 0.24, p = 0.03),中/重度CRS(1级持续发烧或≥2级;β = -0.25, p = 0.03), ICANS(任何分级;β = -0.22, p = 0.04)与较低的Δ6MWD显著相关。结论:这项现实世界的研究表明,如果康复治疗得当,即使在老年患者中,car - t细胞治疗也不太可能降低身体功能,而CRS和ICANS可能是剥夺运动耐量的危险因素。
{"title":"Fluctuation of physical function during chimeric antigen receptor T-cell therapy during rehabilitation intervention: Real-world data and risk factor analyses","authors":"Ryota Hamada,&nbsp;Yasuyuki Arai,&nbsp;Toshio Kitawaki,&nbsp;Naokazu Nakamura,&nbsp;Masanobu Murao,&nbsp;Michiko Matsushita,&nbsp;Junsuke Miyasaka,&nbsp;Tsugumi Asano,&nbsp;Tomoyasu Jo,&nbsp;Momoko Nishikori,&nbsp;Junya Kanda,&nbsp;Chisaki Mizumoto,&nbsp;Kouhei Yamashita,&nbsp;Ryosuke Ikeguchi,&nbsp;Akifumi Takaori-Kondo","doi":"10.1002/jha2.1043","DOIUrl":"10.1002/jha2.1043","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Patients undergoing chimeric antigen receptor (CAR) T-cell therapy face prolonged treatment timelines and are prone to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) after infusion. Disabilities in physical function and the importance of rehabilitation during CAR-T-cell therapy to maintain physical function have been poorly documented.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>We performed a retrospective cohort study to assess changes in exercise tolerance via differences in a 6-min-walking distance (Δ6MWD) and factors influencing it.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 77 patients who underwent rehabilitation during CAR-T-cell therapy were enrolled, and their 6MWD was 450 m (median, range 180–705 m) before and 450.5 m (107.0–735.0 m) 30 days after CAR-T treatment. No significant alteration in Δ6MWD was observed overall (11.0 m, 95% confidence interval, −56.1 to 88.2 m). Multiple regression analyses indicated that age (over vs. under 65 years) revealed no notable differences in Δ6MWD (20 vs. 10 m), while ΔHb (<i>β</i> = 0.24, <i>p</i> = 0.03), moderate/severe CRS (grade 1 with continuous fever or grade ≥2; <i>β</i> = −0.25, <i>p</i> = 0.03), and ICANS (any grade; <i>β</i> = −0.22, <i>p</i> = 0.04) were significantly associated with lower Δ6MWD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This real-world study indicated that CAR-T-cell therapy is less likely to reduce physical function even in older patients if rehabilitation is properly performed, whereas CRS and ICANS can be risk factors to deprive exercise tolerance.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"5 6","pages":"1252-1259"},"PeriodicalIF":0.0,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
EJHaem
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1